Philosophy of Care
Dr. Jonas believes in high quality, innovative, and compassionate care of his patients. Dr. Jonas believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.
Dr. Jonas' clinical interests include: acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia and other hematologic malignancies.
Dr. Jonas specializes in acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia and other hematologic malignancies. His clinical and translational research focuses on the development and application of novel therapeutic agents for acute leukemias and MDS. In particular, Dr. Jonas is interested in leukemia stem cell biology and development of novel aniti-leukemia stem cell therapeutics.
Hematology and Oncology
M.D., UC Davis School of Medicine, Davis CA 2007
Ph.D., Biochemistry and Molecular Biology, UC Davis School of Medicine, Davis CA 2007
B.A., UC Berkeley, Berkeley CA 1999
Internship: Stanford Clinical Investigator Pathway, Stanford University School of Medicine, Stanford CA 2007-2008
Stanford Clinical Investigator Pathway, Stanford University School of Medicine, Stanford CA 2008-2009
Hematology and Oncology, Stanford University School of Medicine, Stanford CA 2009-2013
American Board of Internal Medicine,
American Board of Internal Medicine, Hematology,
Drug Enforcement Administration Registration,
Medical Board of California, Physician and Surgeon License,
American Association for Cancer Research
American College of Physicians
American Medical Association
American Physician-Scientist Association
American Society of Clinical Oncology Associate Member
American Society of Hematology
Association of Northern California Oncologists (ANCO)
California Cancer Consortium
California Medical Association
Myelodysplastic Syndrome Foundation
Southwest Oncology Group (SWOG)
UC Hematologic Malignancies Consortium
Honors and Awards
Internal Medicine Outstanding Clinician Award, UC Davis Department of Internal Medicine, 2020
Highest Accrual, Hematologic Malignancies Clinical Trials, UC Davis Comprehensive Cancer Center, 2015, 2016, 2017, 2018, 2019, 2020
Elected to Fellow in the American College of Physicians (FACP), 2019
Named Sacramento Magazine Top Doctor Hematology/Oncology, 2018, 2019
Named to M3814 CTEP/NCI Project Team, 2018
Named to Pevonedistat CTEP/NCI Project Team, 2017
SWOG Leadership Academy Award, 2017
Honored for Founding the WeCARE! Blood Cancer Peer Navigator Program, 2015
K12 Scholar Award, UC Davis Paul Calabresi Clinical Oncology K12 Program, NIH/NCI, 2014, 2015, 2016, 2017
Fellowship Award, Stem Cell Training Program, California Institute for Regenerative Medicine, 2013, 2014
Special Fellow in Clinical Research Award, Leukemia & Lymphoma Society Career Development Program, 2013
Loren D. Carlson Student Research Award, UC Davis School of Medicine, 2007
Allan T. Nunn, MD Memorial Scholarship in Oncology, UC Davis School of Medicine, 2007
Alpha Omega Alpha (AOA), Eta California Chapter, UC Davis, 2006
Phi Sigma Biological Sciences Honor Society, Gamma Delta Chapter, UC Davis, 2004
Physician-Scientist Training Program Fellowship Award, UC Davis School of Medicine, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007
UC Regents Scholarship, UC Davis School of Medicine, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007
Phi Beta Kappa Society, Alpha Chapter, UC Berkeley, 1999
Golden Key Honor Society, UC Berkeley, 1999
Select Recent Publications
For a comprehensive list of Dr. Jonas' publications, please click here
Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):453-458. doi:10.1016/j.clml.2020.02.006. Epub 2020 Feb 20.
Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov;94(11):E291-E294. doi:10.1002/ajh.25605. Epub 2019 Aug 20.
Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019 Dec;33(12):2795-2804. doi:10.1038/s41375-019-0612-8. Epub 2019 Oct 18.
Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):509-515.e1. doi:10.1016/j.clml.2019.05.008. Epub 2019 May 13.
Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine. 2019 Aug;20:102004. doi:10.1016/j.nano.2019.04.007. Epub 2019 May 2.
Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 2019 Jul;20(7):984-997.
Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 2019 Jul;94(7):803-811. Published online 2019 May 1. doi:10.1002/ajh.25484.
Malfatti MA, Buchholz BA, Enright HA, Stewart BJ, Ognibene TJ, McCartt AD, Loots GG, Zimmermann M, Scharadin TM, Cimino GD, Jonas BA, Pan CX, Bench G, Henderson PT, Turteltaub KW. Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. Toxics. 2019 Jun;7(27):1-22. Published online 2019 May 9. doi:10.3390/toxics7020027.
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 Jun;133(1):7-17. doi:10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
Galkin M, Jonas BA. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. Core Evid. 2019;14: 3–17. Published online 2019 Apr 26. doi:10.2147/CE.S172912.